Quick Takeaways
- EcoR1 Capital, LLC filed SCHEDULE 13G/A for Kalaris Therapeutics, Inc. Common Stock (KLRS).
- Disclosed ownership: 1.1%.
- Date of event: 31 Mar 2025.
EcoR1 Capital, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Kalaris Therapeutics, Inc. Common Stock (KLRS)
- Filing Manager
- EcoR1 Capital, LLC
- Reporting Manager
- EcoR1 Capital, LLC
- Symbol
- KLRS
- Shares outstanding
- 18,338,000 shares
- Disclosed Ownership
- 201,718 shares
- Ownership
- 1.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 14:06:53 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"EcoR1 Capital, LLC disclosed 1.1% ownership in Kalaris Therapeutics, Inc. Common Stock (KLRS) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 14:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 1.1% | 201,718 | 0 | 201,718 | /s/ Oleg Nodelman | Manager | |
| Oleg Nodelman | 1.1% | 201,718 | 0 | 201,718 | /s/ Oleg Nodelman | Reporting person | |
| EcoR1 Capital Fund Qualified, L.P. | 1% | 191,242 | 0 | 191,242 | /s/ Oleg Nodelman | Manager of the General Partner, EcoR1 Capital, LLC |